Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
IRF2BP2 encodes an interferon regulatory factor-2 (IRF2) binding protein that interacts with the C-terminal transcriptional repression domain of IRF2. Additionally we are shipping IRF2BP2 Kits (4) and and many more products for this protein.
Showing 10 out of 64 products:
Human Polyclonal IRF2BP2 Primary Antibody for EIA, FACS - ABIN952948
Beausoleil, Jedrychowski, Schwartz, Elias, Villén, Li, Cohn, Cantley, Gygi: Large-scale characterization of HeLa cell nuclear phosphoproteins. in Proceedings of the National Academy of Sciences of the United States of America 2004
Show all 2 references for 952948
A novel IRFBP2 mutation was identified in a family with autosomal dominant CVID (show TNFRSF13B Antibodies). Transduction experiments suggest that the mutant protein has an effect on B-cell differentiation and is likely a monogenic cause of the family's CVID (show TNFRSF13B Antibodies) phenotype.
ETO2 and IRF2BP2 interacting with the NCOR1/SMRT co-repressor complex, suppresses the expression of erythroid genes until erythroid differentiation.
A deletion variant that lowers IRF2BP2 expression predisposes to coronary artery disease in humans.
analysis of an IRF2BP2-CDX1 (show CDX1 Antibodies) fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma
Nuclear localization of IRF2BP2 depends on phosphorylation near a conserved NLS (show ALDH1A2 Antibodies). Changes in phosphorylation status likely control nucleocytoplasmic localization of IRF2BP2 during muscle differentiation.
results indicate that DIF-1 plays a key role in breast cancer cell survival
Data demonstrate that IRF-2BP2 is a negative regulator of the NFAT1 (show NFAT1 Antibodies) transcription factor and suggest that NFAT1 (show NFAT1 Antibodies) repression occurs at the transcriptional level.
IRF2BP2 works with TEAD transcription factors to upregul (show VEGFA Antibodies)ate the expression of VEGFA in skeletal and cardiac muscle. IRF2BP2 protein levels are increased in response to tissue ischemia.
Identification of IRF-2 binding protein 1 (show IRF2BP1 Antibodies) and IRF-2 binding protein 2 as co-repressor molecules for interferon regulatory factor-2 (show IRF2 Antibodies).
Irf2bp2 gene expression was decreased in CD4 (show CD4 Antibodies) T cells upon activation. Ectopic expression of IRF2BP2 led to a reduction in CD25 (show IL2RA Antibodies) expression and STAT5 (show STAT5A Antibodies) phosphorylation, along with an impaired proliferative capacity. IRF2BP2 overexpression in differentiated Th cells resulted in reduced IL-4 (show IL4 Antibodies) and pro-TGF-beta (show TGFB1 Antibodies) production in Th2 and iTregs but had no effect on IFN-gamma (show IFNG Antibodies) or IL-17 (show IL17A Antibodies) expression in Th1 (show HAND1 Antibodies) and Th17 cells, respectively.
IRF2BP2 as a novel negative regulator in controlling pathological Cardiac Hypertrophy at the transcriptional level was defined.
Ablation of IRF2BP2 in macrophages worsens atherosclerosis in mice.
IRF2BP2 is a novel ischemia-induced coactivator of VEGFA (show VEGFA Antibodies) expression that may contribute to revascularization of ischemic cardiac and skeletal muscles.
This gene encodes an interferon regulatory factor-2 (IRF2) binding protein that interacts with the C-terminal transcriptional repression domain of IRF2. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
IRF-2-binding protein 2
, interferon regulatory factor 2-binding protein 2
, putative nuclear protein of bilaterial origin (49.6 kD) (5N852)